{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T02:52:23Z","timestamp":1767149543811,"version":"build-2238731810"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Obesity Pillars"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.obpill.2024.100138","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T13:32:07Z","timestamp":1727703127000},"page":"100138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Retrospective review of seven patients with obesity simultaneously treated with a combination of a glucagon-like peptide-1 receptor agonist and a meal replacement product"],"prefix":"10.1016","volume":"12","author":[{"given":"Catherine","family":"Bacus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terri-Lynne","family":"South","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Raudszus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2470-0530","authenticated-orcid":false,"given":"Odd Erik","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.obpill.2024.100138_bib1","first-page":"1","article-title":"The latest evidence and clinical guidelines for use of meal replacements in very-low-calorie diets or low-calorie diets for the treatment of obesity","author":"Edwards-Hampton","year":"2024","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.obpill.2024.100138_bib2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/oby.2007.531","article-title":"Higher protein intake preserves lean mass and satiety with weight loss in pre-obese and obese women","volume":"15","author":"Leidy","year":"2007","journal-title":"Obesity"},{"key":"10.1016\/j.obpill.2024.100138_bib3","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/dom.15392","article-title":"The OPTIFAST total and partial meal replacement programme reduces cardiometabolic risk in adults with obesity: secondary and exploratory analysis of the OPTIWIN study","volume":"26","author":"Ard","year":"2024","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.obpill.2024.100138_bib4","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.orcp.2022.08.003","article-title":"The Australian Obesity Management Algorithm: a simple tool to guide the management of obesity in primary care","volume":"16","author":"Markovic","year":"2022","journal-title":"Obes Res Clin Pract"},{"key":"10.1016\/j.obpill.2024.100138_bib5","doi-asserted-by":"crossref","first-page":"E875","DOI":"10.1503\/cmaj.191707","article-title":"Obesity in adults: a clinical practice guideline","volume":"192","author":"Wharton","year":"2020","journal-title":"CMAJ (Can Med Assoc J)"},{"key":"10.1016\/j.obpill.2024.100138_bib6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1475-2891-6-12","article-title":"Nutrient adequacy during weight loss interventions: a randomized study in women comparing the dietary intake in a meal replacement group with a traditional food group","volume":"6","author":"Aashley","year":"2007","journal-title":"Nutr J"},{"key":"10.1016\/j.obpill.2024.100138_bib7","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1105816","article-title":"Long-term persistence of hormonal adaptations to weight loss","volume":"365","author":"Sumithran","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.obpill.2024.100138_bib8","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3390\/bs10090136","article-title":"Attitudes and approaches to use of meal replacement products among healthcare professionals in management of excess weight","volume":"10","author":"Maston","year":"2020","journal-title":"Behav Sci"},{"key":"10.1016\/j.obpill.2024.100138_bib9","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.eprac.2021.11.082","article-title":"Is obesity or adiposity-based chronic disease curable: the set point theory, the environment, and second-generation medications","volume":"28","author":"Garvey","year":"2022","journal-title":"Endocr Pract"},{"key":"10.1016\/j.obpill.2024.100138_bib10","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/dom.12932","article-title":"Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity","volume":"19","author":"Blundell","year":"2017","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.obpill.2024.100138_bib11","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2147\/CLEP.S391819","article-title":"Efficacy and safety of liraglutide and semaglutide on weight loss in people with obesity or overweight: a systematic review","volume":"14","author":"Xie","year":"2022","journal-title":"Clin Epidemiol"},{"issue":"24","key":"10.1016\/j.obpill.2024.100138_bib12","article-title":"Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions","volume":"S2468-1253","author":"Jalleh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.obpill.2024.100138_bib13","unstructured":"US Food and Drug Administration. Semaglutide package insertion. Available from:: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215256s000lbl.pdf."},{"key":"10.1016\/j.obpill.2024.100138_bib14","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.obpill.2024.100138_bib15","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1161\/CIRCULATIONAHA.124.069680","article-title":"Digital footprints of obesity treatment: GLP-1 receptor agonists and the health equity divide","volume":"150","author":"Azizi","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.obpill.2024.100138_bib16","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s00268-021-06394-9","article-title":"Guidelines for perioperative care in bariatric surgery: enhanced recovery after surgery (eras) society recommendations: a 2021 update","volume":"46","author":"Stenberg","year":"2022","journal-title":"World J Surg"},{"key":"10.1016\/j.obpill.2024.100138_bib17","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13543","article-title":"Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: a network meta-analysis of randomized clinical trials","volume":"24","author":"Alkhezi","year":"2023","journal-title":"Obes Rev"},{"key":"10.1016\/j.obpill.2024.100138_bib18","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ijo.2013.120","article-title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study","volume":"37","author":"Wadden","year":"2013","journal-title":"Int J Obes"},{"key":"10.1016\/j.obpill.2024.100138_bib19","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/ijo.2014.177","article-title":"Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss","volume":"39","author":"Iepsen","year":"2015","journal-title":"Int J Obes"},{"key":"10.1016\/j.obpill.2024.100138_bib20","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"issue":"Suppl 6","key":"10.1016\/j.obpill.2024.100138_bib21","doi-asserted-by":"crossref","first-page":"71","DOI":"10.7861\/clinmed.23-6-s71","article-title":"Addition of very low calorie diet (VLCD) during initiation of semaglutide in individuals with type 2 diabetes - interim results","volume":"23","author":"Anyiam","year":"2023","journal-title":"Clin Med"},{"key":"10.1016\/j.obpill.2024.100138_bib22","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/oby.22359","article-title":"Intensive behavioral therapy for obesity combined with liraglutide 3.0 mg: a randomized controlled trial","volume":"27","author":"Wadden","year":"2019","journal-title":"Obesity"},{"key":"10.1016\/j.obpill.2024.100138_bib23","article-title":"Weight regain after total meal replacement very low-calorie diet program with and with-out anti-obesity medications","volume":"10","author":"Cifuentes","year":"2023","journal-title":"Obes Sci Pract"},{"issue":"2 Suppl","key":"10.1016\/j.obpill.2024.100138_bib24","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.1378\/chest.95.2_Supplement.2S","article-title":"Rules of evidence and clinical recommendations on the use of antithrombotic agents","volume":"95","author":"Sackett","year":"1989","journal-title":"Chest"}],"updated-by":[{"DOI":"10.1016\/j.obpill.2024.100144","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000}}],"container-title":["Obesity Pillars"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368124000408?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368124000408?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T23:47:59Z","timestamp":1733269679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667368124000408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":24,"alternative-id":["S2667368124000408"],"URL":"https:\/\/doi.org\/10.1016\/j.obpill.2024.100138","relation":{},"ISSN":["2667-3681"],"issn-type":[{"value":"2667-3681","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retrospective review of seven patients with obesity simultaneously treated with a combination of a glucagon-like peptide-1 receptor agonist and a meal replacement product","name":"articletitle","label":"Article Title"},{"value":"Obesity Pillars","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.obpill.2024.100138","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of Obesity Medicine Association.","name":"copyright","label":"Copyright"}],"article-number":"100138"}}